Action was muted this morning to start the second quarter earnings season. Major financial firms start to release data today, beginning with Goldman Sachs (GS) who posted an earnings beat before the bell today. This marks the second straight quarter of better than expected earnings for the banking firm. GS shares traded slightly higher in early trading. Investors will be watching for clues on inflation as June CPI and other key metrics will be discussed in the coming days.
One area of the market that can offer hefty returns is biotech. It’s not unheard of for a winning biotech stock to produce 10x or 20x returns in a very short period of time. But biotech companies are difficult to evaluate due to the speculative nature of their technologies, and due to the breadth of knowledge, experience, and education required to understand them. Although this is true for all industries, it is particularly true for biotech.
Specifically, genomics is one niche within the biotech group that could offer unimaginable returns, but the technology is so new and so advanced, many investors shy away from companies that are making astounding advancements.
One solution is to delegate individual stock picking to the professionals. In today’s trade we’ll focus on an exchange-traded fund (ETF) that provides an opportunity for investors who are looking to gain access to companies at the forefront of genomics innovation.
New in Biotech:
The Guardian: “New pill could spell the end of all disease.”
This pill is set to completely change the lives of millions of Americans.
And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…
Investors who get in on the ground floor stand to become rich beyond their wildest dreams. [Full Story…]
iShares Genomics Immunology and Healthcare ETF (IDNA)
IDNA holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. The fund is passively managed and holdings are weighted by market-cap and are constrained such that no individual security exceeds 4% weight of the portfolio. The index rebalances semi-annually.
It’s worth noting that IDNA beat Cathie Woods’ ARK Genomic Revolution ETF (ARKG) in the first ten weeks of 2020, when global markets were rocked by the coronavirus outbreak and investors were eagerly hunting for potential profit in companies researching treatment and vaccines.
- Weighted Average Market Cap $22.53B
- Price / Earnings Ratio -39.69
- Price / Book Ratio 4.76
- YTD Daily Total Return -2.55%
- YTD Return -0.96%
- Yield 0.25%
- Expense Ratio 0.47%
- Net Assets 297.12M
- Number of Holdings 50
- Top Holdings: BioNtech SE BNTX, BeiGene Ltd BGNE, Fate Therapeutics FATE
Where to invest $1,000 right now...
Before you consider buying IDNA, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not IDNA.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
Palm Beach Group:
Teeka: “Buy this Ticker ASAP” – DONT USE.
With experts projecting gains as high as 1,530% by the end of this year… Anyone who doesn’t buy this ticker will most likely regret it later. Even Forbes has confirmed that when all is said and done, “a new class of millionaires may emerge.” Unfortunately, a recent study shows that only 3% of retirees have invested in this opportunity. That means most people will miss out. Don’t be one of them. Click here and get the ticker now… no strings attached. [REVEAL TICKER]